Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975  
5/15/2012 10:33:55 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults. Achaogen is developing plazomicin, a next-generation aminoglycoside that overcomes common bacterial resistance mechanisms, as an intravenous treatment for serious Gram-negative bacterial infections, including those caused by multi-drug resistant (MDR) Escherichia coli and Klebsiella pneumoniae. In addition, the Biomedical Advanced Research and Development Authority (BARDA) previously awarded Achaogen up to $64.5 million in funding to support the development of plazomicin as a potential medical countermeasure against the biothreat pathogens, Yersinia pestis and Francisella tularensis.